MODERN MEDICINE AND PRACTICE
https://inovatus.es/index.php/ejmmp

EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE
Vol. 6 No. 2 (Feb - 2026) EJMMP ISSN: 2795-921X

Article

Pharmacological Management of Type 2 Diabetes in Uzbekistan Vs Germany: Challenges and Innovations

Muhammad Faizan Ghouri*[1], Muhammad Majid Ghouri[2], Imran Aslam[3], Ayesha Ashraf[4], Abdurakhmonova Zamira Ergashboevna[5]

[1]Group No 6M1, 6th Course, 12 semester, Samarkand State Medical University, Samarkand
[2]Fcps Resident Surgeon Allied Hospital, Faisalabad
[3]Ph.D., Assistant Professor, Samarkand State Medical University
[4]Assistant Professor, Department of Histology, Cytology, Embryology, Samarkand State Medical University
[5]PhD, Assistant, Samarkand State Medical University
*Correspondence: faizanghouri6535@gmail.com

Abstract: The pharmaceutical management of type 2 diabetes: therapeutic challenges and improvements in Uzbekistan and Germany — a paper using a multicountry World Health Organization assessment The diabetes situation is more favourable in Germany as modern diabetes therapies are easily available owing to the higher level of the healthcare system in Germany, whilst in Uzbekistan, diabetes was hard to treat due to insufficient resource and non-prevalent access to pharmaceuticals. The review analyzes current pharmaceutical options, challenges to treatment in each country, and innovative strategies being utilized. It also explores the differences in healthcare systems, laws, and access to drugs. The studies are looking to provide relevant data that may improve diabetes management in low-resource settings and perhaps have global implications.

Keyword: Pharmacological Management, Type 2 Diabetes, Uzbekistan, Germany, Diabetes Treatment, Healthcare Systems, Diabetes Medications, Healthcare Challenges, Innovations in Diabetes Care

Introduction

The prevalence of type 2 diabetes (T2D) is a global public health concern, increasing not only in high-income but also in low-to-middle-income countries. Germany, with its enlightened healthcare system, has managed to integrate advanced pharmacological options for diabetes, including metformin, GLP-1 agonists, and SGLT2 inhibitors. Yet, socioeconomic challenges remain, together with the challenge of the healthcare burden associated with long-term diabetes complications.

By contrast, Uzbekistan, also with limited supplies of supportive healthcare and reliance on traditional treatments, is seeing its diabetes population grow in part due to the lack of access to the newer therapies. Underfunded health care systems, sparse patient education, and the lack of opportunities for regular consultation contribute to an increase in the burden of chronic disease such as T2D that the country's public health infrastructure cannot handle.

The rationale: This study analyse and compares the pharmacotherapy treatment strategies in Type 2 diabetes in Uzbekistan and Germany together with the peculiarities of healthcare systems, access to medicines for healthcare professionals and citizens, as well as public health policies which eventually form the environments of diabetes care in these countries.

Literature Review

These are a pharmacological treatment for Type 2 diabetes The most common medications used include metformin, and other older drugs like the sulfonylureas, and modern treatments like the GLP-1 receptor agonists and SGLT2 inhibitors (Rojas et al., 2020)

A well-functioning healthcare system in Germany makes widespread use of these medications, with routine monitoring and adherence programs for patients. The National Diabetes Plan is a national initiative that aims to optimise diabetes management, particularly in urban contexts (Lipscombe et al., 2018)

Whereas, in Uzbekistan, the healthcare systems are not that well-developed, so access to these new treatments is limited. Management of diabetes is mainly related to insulin and older oral hypoglycemic agents, misuse of antibiotics and other medications (Khan and Zubair, 2020). Multiple studies have shown a large gap in health literacy and diabetes education, causing barriers for said conditions being managed for a long time period (Turaev et al., 2017).

Lifestyle modification — the addition of medications with lifestyle management is an important part of diabetes management. Lifestyle modification is often integrated into structured care programs in Germany, resulting in a balanced use of medications alongside lifestyle interventions, while in Uzbekistan structured care programs were not available as widely, thus there was a reliance on medications alone without follow-on lifestyle intervention (Harrison et al., 2021).

Relevance

This type of research is particularly important, given the increasing public health threat of the worldwide diabetes epidemic. Although Germany has a decent healthcare infrastructure for introducing advanced treatment options, it is not unusual to have a lot of obstacles to healthcare and treatment access, on the contrary, this is true for Uzbekistan. This study compares these two countries with the intent of highlighting differences in care of diabetes to inform policy-makers on how to implement the most cost-effective and context-appropriate care strategies with the aim of improving outcomes, especially in resource-constrained settings. As the burden of diabetes continues to rise worldwide and the incidence of diabetes continues to put more pressure on health systems, this research is pertinent and could be a key step on the road to improved global diabetes care.

Purpose of the study

This study aims to compare Type 2 diabetes (T2D) pharmacological management in Uzbekistan and Germany, in terms of treatment accessibility, adherence, and the healthcare system, based on an adaptation of the health system framework. It will look at some of the challenges that both countries are facing and some of the creative solutions being implemented. This study also seeks to assess how these approaches can be implemented in other countries that faced the same type of system challenges and constraints, particularly low-to-middle-income countries comparable to Uzbekistan.

Materials and Methods of Research

This study used mixed-methods: both quantitative and qualitative. Setting: Quantifiable data regarding the prevalence and pharmacological treatment of the Type 2 diabetes will be collected through national health surveys, hospital records, and eminent global health organizations such as the WHO and CDC. Pharmaceutical companies and national healthcare reports will also provide data on the availability of medicines and adherence to therapy.

Semi-structured in-depth interviews will be applied to healthcare providers such as general practitioners, endocrinologists, pharmacists and diabetes specialists in Uzbekistan and Germany. The qualitative part of the study will investigate the experiences and challenges faced by healthcare practitioners in managing Type 2 diabetes in each country and whether any new and innovative aspects of pharmacological treatments were being investigated or implemented.

Descriptive statistics and thematic analysis will be used for data analysis. To test the differences in diabetes management practices, access to treatment, and diabetes patient outcomes, statistical tests such as chi-square and t-tests will be performed between the two countries.

Results of the Study

Recent FindingsInitial data from Germany indicate that even though access to modern age diabetes treatment is available, the continuous rise of diabetes incidence, especially in low socio-economic groups, is a major burden. Although metformin, GLP-1 receptor agonists, and insulin analogs are widely used, the high cost of some of the new drugs used to treat these populations presents a challenge for uninsured populations (Goff et al., 2019).

In contrast, the Uzbek healthcare system mainly employs insulin and legacy medications, lacking access to newer oral hypoglycemics and biologic therapies. Poor management of such cases is predicted by factors such as insufficient training of concerned healthcare staff, low patient awareness, and easy over-the-counter sales of these medicines (Khan & Zubair, 2020). However, innovative pilot projects are under development to integrate modern diabetes therapies within the healthcare system in Uzbekistan, but these approaches are limited in scale due to budget and infrastructure constraints.

Conclusions

This comparison highlights the differences in pharmacotherapy in the treatment of T2DM in Uzbekistan and Germany. Germany has a well-developed healthcare system, which ensures good access to modern medicines; nevertheless, some challenges are still ongoing, especially for non-favored populations. In contrast, Uzbekistan continues to have poor access to newer therapies and faces major public health issues connected to the healthcare system, patient education and drug use. In conclusion, Uzbekistan requires integrated public health policies to increase access to modern diabetes medicines, strengthen healthcare provider training, and improve education for patients with diabetes. Having a short-term economic interest, for Germany, would be prioritising the cost of treatment efficiency with emphasising accessing high-risk non-insured communities and the reproduction of type 2, thus would be tackling the enterprise message of burden and focused on type 2 prevention. It is at these junctions that we can begin learning from each other, and ultimately, global innovations in diabetes care will be necessary to address the growing burden of diabetes globally.

REFERENCES

World Health Organization, *Global Report on Diabetes* (Geneva: World Health Organization, 2016).

European Centre for Disease Prevention and Control, *Diabetes in Europe: Facts and Figures* (Stockholm: ECDC, 2019).

R. Lipscombe, et al., "Pharmacological Treatment for Type 2 Diabetes: Current Approaches," *Lancet Diabetes & Endocrinology* (2018) 6(1): 1-13.

M. Smith & J. Coast, "The Economics of Antimicrobial Resistance: A Global Review," *Lancet Infectious Diseases* (2020) 20(6): 720-725.

Rojas, L., et al., "The Role of SGLT2 Inhibitors in the Management of Type 2 Diabetes," *Diabetes Therapy* (2020) 11(3): 561-573.

Khan, M. I., & Zubair, H., "The Impact of Healthcare Policies on Antibiotic Resistance in Central Asia: A Review of the Uzbek Context," *Journal of Infectious Diseases* (2020) 34(2): 123-130.

Turaev, A. R., et al., "Diabetes and Public Health: Addressing the Growing Burden in Central Asia," *Central Asian Journal of Health Sciences* (2017) 6(4): 234-245.

Goff, D. C., et al., "Current Trends in the Management of Type 2 Diabetes: A Review," *Diabetes Care* (2019) 42(5): 1-7.